Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatment
Copyright © 2022 Duan, Xia, Xu, Chen, Ding, Wang, Sun, Yao, Zhang, Wu, Ji, Wang, Qian, Wang and Shen..
Intravesical bacillus Calmette-Guerin (BCG) instillation is recommended as an adjuvant therapy for intermediate-risk and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBt) with nearly 70% reoccurrence. In the present study, we investigated the dynamics of peripheral purified protein derivative (PPD)-specific immune responses along the treatment. Intravesical BCG instillation caused a significant increase in peripheral PPD-specific IFN-γ release of NMIBC patients, when compared to those receiving chemo-drug instillation. Through a follow-up study, we detected rapid increase in PPD-specific IFN-γ, IL-2, and IL-17A producing CD4+ and CD8+ T cells in the induction phase. Interestingly, the frequencies of PPD-specific IFN-γ and IL-2 producing CD4+ and CD8+ T cells decreased dramatically after induction treatment and were restored after BCG re-instillation, whereas IL-17A-producing T cells remained at the maintenance phase. However, we only observed that the percentages of peripheral CD8+ T cells were significantly higher in BCG responder patients than those in BCG refractory patients at the baseline with the potential of predicting the recurrence. A more dramatic increase in PPD-specific IFN-γ and IL-2 producing CD4+ and CD8+ T cells after one and two dose BCG instillations was observed in refractory NMIBC patients. Therefore, regional BCG instillation induced transient peripheral PPD-specific T cell responses, which could be restored through repetitive BCG instillation. Higher proportions of peripheral CD8+ T cells at baseline were associated with better responses to BCG instillation for the prevention of recurrence of bladder cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 12(2022) vom: 22., Seite 927410 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duan, Huangqi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacillus Calmette-Guerin |
|---|
| Anmerkungen: |
Date Revised 18.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2022.927410 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349004919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349004919 | ||
| 003 | DE-627 | ||
| 005 | 20231226205550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.927410 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349004919 | ||
| 035 | |a (NLM)36387134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duan, Huangqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Duan, Xia, Xu, Chen, Ding, Wang, Sun, Yao, Zhang, Wu, Ji, Wang, Qian, Wang and Shen. | ||
| 520 | |a Intravesical bacillus Calmette-Guerin (BCG) instillation is recommended as an adjuvant therapy for intermediate-risk and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBt) with nearly 70% reoccurrence. In the present study, we investigated the dynamics of peripheral purified protein derivative (PPD)-specific immune responses along the treatment. Intravesical BCG instillation caused a significant increase in peripheral PPD-specific IFN-γ release of NMIBC patients, when compared to those receiving chemo-drug instillation. Through a follow-up study, we detected rapid increase in PPD-specific IFN-γ, IL-2, and IL-17A producing CD4+ and CD8+ T cells in the induction phase. Interestingly, the frequencies of PPD-specific IFN-γ and IL-2 producing CD4+ and CD8+ T cells decreased dramatically after induction treatment and were restored after BCG re-instillation, whereas IL-17A-producing T cells remained at the maintenance phase. However, we only observed that the percentages of peripheral CD8+ T cells were significantly higher in BCG responder patients than those in BCG refractory patients at the baseline with the potential of predicting the recurrence. A more dramatic increase in PPD-specific IFN-γ and IL-2 producing CD4+ and CD8+ T cells after one and two dose BCG instillations was observed in refractory NMIBC patients. Therefore, regional BCG instillation induced transient peripheral PPD-specific T cell responses, which could be restored through repetitive BCG instillation. Higher proportions of peripheral CD8+ T cells at baseline were associated with better responses to BCG instillation for the prevention of recurrence of bladder cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bacillus Calmette-Guerin | |
| 650 | 4 | |a cytokine profiles | |
| 650 | 4 | |a non-muscle invasive bladder cancer (NMIBC) | |
| 650 | 4 | |a peripheral immune responses | |
| 650 | 4 | |a predictor | |
| 700 | 1 | |a Xia, Weimin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ding |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ruiming |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Chengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shun |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shujun |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Subo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Haibo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 22., Seite 927410 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:22 |g pages:927410 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.927410 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 22 |h 927410 | ||